SCHEMBL2962995

SCHEMBL2962995

CC(C)c1nnc(NS(=O)(=O)c2cc3c(cc2Cl)C[CH]C3C(N)=O)s1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 6/20 0.37
RAB9A P51151 6/20 0.37
MAPT P10636 4/20 0.37
TP53 P04637 3/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
KMT2A Q03164 3/20 0.37
UBE2N P61088 1/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 2/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960589 0.83 ALDH1A1 (0.49) ALDH1A1HSD17B10NPC1RAB9AMAPT
SCHEMBL2962997 0.78 ALDH1A1 (0.44) ALDH1A1HSD17B10NPC1RAB9AMAPT
SCHEMBL5409824 0.65 HSD11B1 (0.51) ALDH1A1HSD17B10NPC1RAB9AMAPT
SCHEMBL2968217 0.64 ALDH1A1 (0.50) ALDH1A1HSD17B10NPC1RAB9AMAPT
SCHEMBL5404610 0.63 ALDH1A1 (0.71) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL2960594 0.62 ALDH1A1 (0.56) ALDH1A1HSD17B10LMNAKMT2A
SCHEMBL3788760 0.61 ALDH1A1 (0.61) ALDH1A1HSD17B10LMNASMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL1968225 0.61 ALDH1A1 (0.55) ALDH1A1HSD17B10LMNAKMT2A
SCHEMBL1972440 0.61 CA1 (0.55) ALDH1A1HSD17B10KMT2A
SCHEMBL5396223 0.61 ALDH1A1 (0.51) ALDH1A1HSD17B10NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772257-B2 Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20100022603-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE SANOFI-AVENTIS (FR) 2010-01-28 US disclosed
US-7612104-B2 Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use SANOFI-AVENTIS (FR) 2009-11-03 US disclosed
US-20080293780-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE SANOFI-AVENTIS (FR) 2008-11-27 US disclosed
EP-1937675-A2 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007039174-A2 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293780-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE PPARG, PPARA, PPARD ALDH1A1 1019/4885HSD17B10 617/4885NPC1 1054/4885
US-20100022603-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE PPARG, PPARA, PPARD ALDH1A1 1072/4885HSD17B10 622/4885NPC1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.